WO 2005/007676 PCT/US2004/022134

## CLAIMS

What is claimed is:

5

1. A method for treating a metabolic or autoimmune disorder in a human or veterinary patient, said method comprising the step of


234

1

(A) administering to the patient a therapeutically effective amount of a compound having the formula:

6

5



8 9

wherein:

10

- 11  $R_1$ ,  $R_2$  and  $R_3$  each represents a hydrogen atom or a  $C_1$ - $C_{22}$  acyl group;
- 12 R<sub>4</sub> represents a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl group;
- 13 R<sub>5</sub> represents a C<sub>1</sub>-C<sub>21</sub> alkyl group or a C<sub>6</sub> or C<sub>,0</sub> aryl group;
- 14 R<sub>6</sub> represents a hydrogen atom; and
- 15 R represents the residue of an amino acid or a linear peptide of up to from 2
- 16 to 6 amino acid residues. Furthermore, at least one of the residues may be
- optionally substituted with a lipophilic group through an ester or amide bond;
- 18 and n is 1 and 2.
- \_
- 1 2. A method according to Claim 1 wherein Step A comprises
- 2 administering GMDP.

WO 2005/007676 PCT/US2004/022134

1 3. A method according to Claim 1 wherein Step A comprises

- 2 administering GMDP-A.
- 1 4. A method according to Claim 1 wherein Step A comprises
- 2 administering GMDP and GMDP-A.
- 1 5. A method according to Claim 4 wherein Step A comprises
- 2 administering GMDP and GMDP-A in separate doses at separate times.
- 1 6. A method according to any of Claims 1-5 wherein the compound is
- 2 administered enterally.
- 1 7. A method according to any of Claims 1-5 wherein the compound is
- 2 administered parenterally.
- 1 8. A method according to Claim 7 wherein the compound is administered
- 2 intranasally.
- 1 9. A method according to Claim 7 wherein the compound is administered
- 2 sublingually.

3

- 1 10. A method according to Claim 7 wherein the compound is administered
- 2 by buccal administration.
- 1 11. A method according to any of Claims 1-10 wherein the method further
- 2 comprises the step of:
- 4 (B) administering to the patient a natural or synthetic compound that
- 5 comprises a flavone, flavonoid, isoflavone or a derivative, prodrug or
- 6 congener thereof.

WO 2005/007676 PCT/US2004/022134

1 12. A method according to Claim 11 wherein Step A and Step B are carried

- 2 out substantially simultaneously.
- 1 13. A method according to Claim 11 wherein Step A and Step B are carried
- 2 out at different times.
- 1 14. A method according to Claim 12 wherein the compound of Step A and
- 2 the compound of Step B are administered in a fixed dosage combination
- 3 pharmaceutical preparation.
- 1 15. The use of a compound having the general formula set forth in Claim 1,
- 2 in the manufacture of a preparation for administration to a human or
- 3 veterinary patient for the treatment of an autoimmune or metabolic disorder.